某院2016年至2020年保肝药临床应用分析

Clinical Application of Hepatoprotective Drugs in a Hospital from 2016 to 2020

目的为临床合理应用保肝药提供参考。方法采用医院用药监测系统(PASS)提取某院2016年至2020年保肝药使用数据,采用世界卫生组织推荐的限定日剂量法,统计并分析相应药物的使用金额及其增长情况和排序,用药频度(DDDs)及排序,限定日费用(DDC),以及使用金额与DDDs的排序比(B/A)。结果该院常用保肝药共16种23品规,其中口服制剂9种9品规,注射制剂9种14品规。口服制剂使用金额年均增长3.46%,注射制剂年均下降24.83%(2019年、2020年降幅均接近50%)。5年间,异甘草酸镁注射液、注射用还原型谷胱甘肽和熊去氧胆酸胶囊的使用金额始终排前5;甘草酸二胺肠溶胶囊、异甘草酸镁注射液、熊去氧胆酸胶囊和多烯磷脂酰胆碱胶囊的DDDs始终排名前5;注射制剂中DDC高于50元的有异甘草酸镁注射液、复方甘草酸单铵S(注射液/粉针剂)、注射用丁二磺酸腺苷蛋氨酸、促肝细胞生长素(注射液/粉针剂)、注射用门冬氨酸鸟氨酸,口服制剂中DDC高于10元的有谷胱甘肽片、熊去氧胆酸胶囊和双环醇片;甘草酸二铵注射液的B/A趋于1。结论该院保肝药用药趋势符合相关指南推荐,其临床使用相对合理。

Objective To provide a reference for the rational use of hepatoprotective drugs in the clinic.Methods The use data on hepatoprotective drugs in a hospital from 2016 to 2020 were extracted by the Prescription Automatic Screening System(PASS),and the defined daily dose(DDD)recommended by the World Health Organization(WHO)was used to count and analyze the consumption sum of corresponding drugs and their growth and ranking,the DDDs and ranking,the defined daily cost(DDC),and the ranking ratio(B/A)of the consumption sum to DDDs.Results There were sixteen kinds(twenty-three specifications)of liver protection drugs commonly used in the hospital,including nine kinds(nine specifications)of oral preparations and nine kinds(fourteen specifications)of injection preparations.The consumption sum of oral preparations increased by 3.46%annually,and the consumption sum of injection preparations decreased by 24.83%annually(the decrease in 2019 and 2020 was close to 50%).In the past five years,the consumption sum of Magnesium Isoglycyrrhizinate Injection,Reduced Glutathione for Injection and Ursodeoxycholic Acid Capsules always ranked in the top five.The DDDs of Diammonium Glycyrrhizinate Enteric-Coated Capsules,Magnesium Isoglycyrrhizinate Injection,Ursodeoxycholic Acid Capsules and Polyene Phosphatidylcholine Capsules always ranked in the top five.The injection preparations with DDC of more than CNY 50 were Magnesium Isoglycyrrhizinate Injection,Compound Monoammonium Glycyrrhizinate S(injection/powder-injection),Ademetionine 1,4-Butanedisulfonate for Injection,Hepatocyte Growth-Promoting Factor(injection/powder-injection),Ornithine Aspartate for Injection,Glutathione Tablets,Ursodeoxycholic Acid Capsules and Dicyclol Tablets,while the oral preparations with DDC of more than CNY 10 were Glutathione Tablets,Ursodeoxycholic Acid Capsules and Dicyclol Tablets.The B/A of Diammonium Glycyrrhizinate Injection was close to one.Conclusion The application of hepatoprotective drugs in the hospital conforms to the recommendations of relevant guidelines,and its clinical use is relatively reasonable.